STAT3 Cancer Research Results

STAT3, Signal transducer and activator of transcription 3: Click to Expand ⟱
Source:
Type: Oncogene
Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response.
Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.)

-STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors.
-Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL).
HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
1029- Ba,  BA,    Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
- vitro+vivo, HCC, NA
PD-L1↓, T-Cell↑, STAT3↓,
5554- BBM,  SRF,    Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
ChemoSen↑, STAT3↓,
5698- BRU,    Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
- in-vitro, HCC, NA
TumCMig↓, EMT↓, STAT3↓, E-cadherin↑, NRF2↓, ChemoSen↑, RadioS↑, DNAdam↑, TumCMig↓, TumCI↓, toxicity↓,
5752- CA,    Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma
- Review, HCC, NA
*ROS↓, angioG↓, STAT3↓, MMP2?, MMP9?,
5892- CAR,  SRF,    Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study
- in-vivo, HCC, NA
Hif1a↓, AFP↑, hepatoP↑, STAT3↓, JAK2↓, *CD8+↑, ChemoSen↑, Dose↝, angioG↓,
1320- EMD,  SRF,    Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7 - vitro+vivo, Hepat, SK-HEP-1
SREBF2↓, Akt↓, TumCCA↑, TumCG↓, STAT3↓,
5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Akt↓, cSrc↓, JAK1↓, JAK2↓, SHP1↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCP↓, Casp3↑, cl‑PARP↑, ChemoSen↑, XIAP↓,
826- GAR,    Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- vitro+vivo, HCC, HepG2 - vitro+vivo, Liver, HUH7
STAT3↓, TumCP↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
1213- VitK2,    Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4
- in-vitro, HCC, HepG2
HSD17B4↓, Akt↓, MEK↓, ERK↓, STAT3↓, TumCP↓,

Showing Research Papers: 1 to 10 of 10

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

NRF2↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

HSD17B4↓, 1,   SREBF2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Bcl-2↓, 2,   Bcl-xL↓, 2,   Casp3↑, 1,   Mcl-1↓, 2,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCsMark↓, 1,   EMT↓, 2,   ERK↓, 1,   mTOR↓, 1,   SHP1↑, 1,   STAT3↓, 10,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   MMP2?, 1,   MMP9?, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hif1a↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

JAK1↓, 1,   JAK2↓, 2,   PD-L1↓, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 4,   Dose↝, 1,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↑, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 1,   toxicity↓, 1,   TumVol↓, 1,  
Total Targets: 45

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: STAT3, Signal transducer and activator of transcription 3
4 Sorafenib (brand name Nexavar)
2 Emodin
1 Baicalein
1 Baicalin
1 Berbamine
1 brusatol
1 Caffeic acid
1 Carvacrol
1 Garcinol
1 Ivermectin
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:373  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page